BETTA PHARMACEUTICALS: Currently, there is no need to provision for the issuance loss of Heyuan Biotechnology
An investor asked Betta Pharmaceuticals: The issuance time of Heyuan has exceeded the expected time and is expected to be unable to issue. Please clarify the specific loss costs. In response, Betta Pharmaceuticals replied on the interactive platform on August 24th that the China Securities Regulatory Commission has approved the registration application for the initial public offering of Wuhan Heyuan Biotechnology Co., Ltd. For specific issuance information, please pay attention to the public information disclosure of Heyuan Biotechnology. Currently, the company does not need to recognize any losses
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments